Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
COHemab Therapeutics Holdings, Inc. logo

Hemab Therapeutics Holdings, Inc. (COAG)

NASDAQ Global Market · Currency in USD
$34.40 ▼ -0.42 (-1.19%)
At close: Oct 23, 4:00 PM ET. Market closed.
$34.40 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:10 PM ET

Summary

Previous Close
$34.82
Open
$34.58
Day's Range
$33.94 – $36.70
52 Week Range
$23.00 – $55.42
Volume
271,177
Avg. Volume
435,711
Market Cap
$1.61B
Beta (5Y Monthly)
1.85
PE Ratio (TTM)
--
EPS (TTM)
-$1.56
Earnings Date
Nov 10, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$51.40

Profile: Hemab Therapeutics Holdings, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
59
CEO
Benny Sorensen
Website
hemab.com

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody.

Earnings

Next report: Tue, Nov 10, 2026
EPS estimate -$0.51
DateEst.Actual
Aug 11, 2026-$0.73-$0.80Miss
May 21, 2026-$23.25-$23.98Miss

Analyst view

Consensus price target
$51.40 ▲ +49.4%
Range $36.00 – $64.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on COAG and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.